PULM Pulmatrix Inc.

1.06
0  0%
Previous Close 1.06
Open 1.09
Price To Book 1.89
Market Cap 19386993
Shares 18,289,616
Volume 505,894
Short Ratio
Av. Daily Volume 2,218,400

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 2Q 2019 with data due 2Q 2020.
Pulmazole (PUR1900)
Allergic bronchopulmonary aspergillosis in patients with asthma.
Phase 2 trial planned.
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Phase 2 ready.
PUR0200
COPD

Latest News

  1. Pulmatrix Announces Leadership Change
  2. Pulmatrix Reports Q1 2019 Results
  3. Pulmatrix and Cipla Technologies LLC enter into Definitive Agreement for the Development and Commercialization of Pulmazole™
  4. Pulmatrix, Inc. Announces Closing of $16.6 Million Upsized Public Offering
  5. Pulmatrix, Inc. Announces Pricing of $14.4 Million Upsized Public Offering
  6. Pulmatrix News: PULM Stock Skyrockets on Asthma Drug Deal
  7. Pulmatrix's stock rockets after deal with Cipla Technologies to develop, commercialize asthma treatment
  8. Pulmatrix Enters Into Binding Term Sheet with Cipla Technologies LLC for the Development and Commercialization of Pulmazole
  9. Pulmatrix to Participate in Upcoming Investor Conferences
  10. Pulmatrix Regains NASDAQ Compliance
  11. These Four Tech Stocks Could Set The Pace On Friday
  12. Pulmatrix Reports 2018 Financial Results; Provides 2019 Outlook on Pulmonary Disease Pipeline
  13. Pulmatrix Receives Five Patents Supporting Claims for their Novel Inhaled Narrow Spectrum Kinase Inhibitor Programs
  14. Pulmatrix, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market
  15. Pulmatrix Receives IND Approval for Pulmazole Phase 2 Clinical Study
  16. 4 Biotech Stocks Making Moves on Wednesday (2/6/19)
  17. Pulmatrix, Inc. Announces Termination of Planned Offering Pursuant to Registration Statement on Form S-1
  18. Pulmatrix, Inc. Announces 1-for-10 Reverse Stock Split
  19. Pulmatrix, Inc. Announces Closing of Public Offering of Common Stock